Schechter Investment Advisors’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Schechter Investment Advisors’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,500	Closed	-$1.77K	–	708
2024 Q4	$1.77K	Sell	15,500 -30,000	-66%	-$3.76K	﹤0.01%	654
2024 Q3	$4.74K	Hold	45,500	–	–	﹤0.01%	657
2024 Q2	$4.6K	Sell	45,500 -1,000	-2%	-$137	﹤0.01%	631
2024 Q1	$6.32K	Hold	46,500	–	–	﹤0.01%	639
2023 Q4	$6.28K	Buy	+46,500	New	+$7.51K	﹤0.01%	618

Schechter Investment Advisors's BLACR Position: Q1 2025 in Review

Schechter Investment Advisors sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 15,500 shares — an estimated $1.77K sold.

Schechter Investment Advisors first reported a position in BLACR in Q4 2023 and held it in 5 quarters. The position peaked at $6.32K in Q1 2024. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Schechter Investment Advisors reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Schechter Investment Advisors sold 15,500 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $1.77K.
Schechter Investment Advisors first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 5 quarters.
Schechter Investment Advisors's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $6.32K in Q1 2024.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Schechter Investment Advisors's 13F filing for Q1 2025, filed 1 May 2025.